⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 1, 2026Transplantation and Cellular Therapy

Outcomes of CAR-T in relapsed/refractory Myeloma with Severe Renal Dysfunction: A Propensity-Matched Analysis

Deevyashali Parekh Shahzad Raza Sandra Mazzoni Jason Valent Louis Williams Jack Khouri Diana Basali Kirti Arora Saveta Mathur Majid Jaberi Faiz Anwer

View at Publisher

Ask AI

Bookmark

Share

Key Points

CAR-T therapy shows improved outcomes in patients with severe renal dysfunction and relapsed myeloma, with a notable response rate.
In a matched analysis of 30 patients, the overall survival rate was significantly higher in those receiving CAR-T treatment.
This propensity-matched analysis involved comparisons based on clinical characteristics to adjust for biases, improving outcome validity.
Future studies need to confirm these findings in more diverse populations to enhance understanding of CAR-T's impact in renal dysfunction cases.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Propensity-matched analysis reveals CAR-T benefits in myeloma patients with renal dysfunction, suggesting effectiveness in complex cases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Parekh et al. (2026) studied this question.

synapsesocial.com/papers/69a76094c6e9836116a2d795 https://doi.org/10.1016/j.jtct.2025.12.607

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD StatusTransplantation and Cellular Therapy · 2026
2Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesTransplantation and Cellular Therapy · 2026
3Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017–2022)Transplantation and Cellular Therapy · 2026
4Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-adapted Prevention StrategyTransplantation and Cellular Therapy · 2026
5Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over timeTransplantation and Cellular Therapy · 2026
6Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French ExperienceTransplantation and Cellular Therapy · 2026
7Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective AnalysisTransplantation and Cellular Therapy · 2026
8Lung Complications after Allogeneic Hematopoietic Cell Transplant and Outcomes: Implications Beyond Bronchiolitis Obliterans SyndromeTransplantation and Cellular Therapy · 2026
9A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy · 2026
10Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regressionTransplantation and Cellular Therapy · 2026

TMore from Transplantation and Cellular Therapy

More from Cleveland Clinic

More from SUNY Upstate Medical University

More from Akron General Medical Center

More from Olathe Medical Center

More from Olathe Public Schools